1. , , Autoreactive T-cells in multiple sclerosis. Int Rev Immunol 1992; 9:183–201.
2. The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36 Suppl:S61–72.
3. , , , , , Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707–17.
4. , , , , , Increased frequency of interleukin 2-responsive T-cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179:973–84.
5. , A theory of self-nonself discrimination. Science 1970; 169:1042–9.
6. A two-step, two-signal model for the primary activation of precursor helper T-cells. Proc Natl Acad Sci USA 1999; 96:185–90.
7. , , T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1:220–8.
8. , , , et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature 1987; 328:267–70.
9. , , , et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15–23.
10. , , , et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362–68.
11. , , , Progressive Multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005.
12. , Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005.
13. , , , , , Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T-cells in patients with multiple sclerosis. Ann N Y Acad Sci 1997; 835:120–31.
14. , , , , , Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T-cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996; 98:70–7.
15. , , , et al. Implication of Th1, Th2, and Th3 cytokines in liver graft acceptance. Transplant Proc 1999; 31:519–20.
16. , The adhesion molecule and cytokine profile of multiple sclerosis lesions [see comments]. Ann Neurol 1995; 37:424–35.
17. , , , , , Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol 1986; 136:3239–45.
18. , Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993; 5:583–8.
19. , , , , Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4 +T-cells via CD40 ligand. Proc Natl Acad Sci USA 1997; 94:599–603.
20. , , , , , Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102:671–8.
21. , , , et al. Human IL-17: a novel cytokine derived from T-cells. J Immunol 1995; 155:5483–6.
22. , , , , TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T-cells. Immunity 2006; 24:179–89.
23. , , , et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T-cells. Nature 2006; 441:235–8.
24. , , , et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441:231–4.
25. , , , , Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910–14.
26. , , , et al. IL-23 drives a pathogenic T-cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233–40.
27. , , , et al. A distinct lineage of CD4 T-cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133–41.
28. , , , et al. Interleukin 17-producing CD4 +effector T-cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123–32.
29. , , , et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009; 66:390–402.
30. , , , , Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005; 11:335–9.
31. , , , et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 1998; 164:63–72.
32. , T-cell memory. Annu Rev Immunol 2002; 20:551–79.
33. , , T-cell memory. Annu Rev Immunol 1998; 16:201–23.
34. , , Differential activation requirements for virgin and memory T-cells. J Immunol 1988; 141:3249–57.
35. , , , , Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T-cells cannot be overcome by CD28 costimulation. Eur J Immunol 1994; 24:1956–60.
36. , , Functional and ontogenetic analysis of murine CD45Rhi and CD45Rlo CD4+ T-cells. J Immunol 1990; 144:3288–95.
37. , Differentiation of T-cell lymphokine gene expression: the in vitro acquisition of T-cell memory. J Exp Med 1991; 173:25–36.
38. , , , et al. Helper T-cell differentiation is controlled by the cell cycle. Immunity 1998; 9:229–37.
39. , , , , CD4+CD28- costimulation-independent T-cells in multiple sclerosis. J Clin Invest 2001; 108:1185–94.
40. , , , Human CD4(+)CD25(+) thymocytes and peripheral T-cells have immune suppressive activity in vitro. Eur J Immunol 2001; 31:1247–54.
41. , , , , Ex vivo isolation and characterization of CD4(+)CD25(+) T-cells with regulatory properties from human blood. J Exp Med 2001; 193:1303–10.
42. , , , CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245–53.
43. , , Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T-cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193:1295–302.
44. , Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T-cell clones. J Immunol 1990; 144:32–40.
45. , , , et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179:493–502.
46. , , , Activated self-MHC-reactive T-cells have the cytokine phenotype of Th3/T regulatory cell 1 T-cells. J Immunol 2000; 165:691–702.
47. , The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol 2000; 12:676–83.
48. , , , Loss of functional suppression by CD4+CD25+ regulatory T-cells in patients with multiple sclerosis. J Exp Med 2004; 199:971–9.
49. , , , , Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol 1991; 30:42–7.
50. , , , , , Alterations in levels of CD28-/CD8 +suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol 1995; 2:249–52.
51. , Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001; 79:552–65.
52. , , , , , Increased frequency of interleukin 2-responsive T-cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179:973–84.
53. , , , T-cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990; 247:718–21.
54. , , , et al. Frequency of T-cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38:105–13.
55. , , , , , Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T-cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 1997; 100:1114–22.
56. , , Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Proc Natl Acad Sci USA 1995; 92:8896–900.
57. , , , , Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T-cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J Exp Med 1994; 180:2227–37.
58. , , , et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6:1167–75.
59. , , , et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000; 6:1176–82.
60. , , , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268–76.
61. , , , et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000; 54:813–17.
62. , , , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995. Neurology 2001; 57:S16–24.
63. , , , , Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105:967–76.
64. , , , Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. Cell Immunol 1995; 163:229–36.
65. , , , Copolymer-1-induced inhibition of antigen-specific T-cell activation: interference with antigen presentation. J Neuroimmunol 1992; 37:75–84.
66. , , , , In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T-cells in patients with multiple sclerosis. Clin Immunol 2003; 106:163–74.
67. , , , , , Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 2000; 97:11472–7.
68. , , , et al. Type II monocytes modulate T-cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13:935–43.
69. , , , et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T-cell responses in patients with multiple sclerosis. J Clin Invest 2002; 109:641–9.
70. The clonal selection theory of acquired immunity. In: Vanderbilt University Press; 1959; Nashville, Tennessee, USA, 1959.
71. , Oral tolerance. Immunol Rev 2005; 206:232–59.
72. , , , et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259:1321–4.
73. , Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999; 73:153–264.
74. , , Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci USA 1999; 96:3842–7.
75. , , , , Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial. Ann Neurol 2000; 47:686.
76. , , , , Depletion of myelin-basic-protein autoreactive T-cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 1995; 346:807–8.
77. , , , et al. T-cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol 2002; 249:212–18.
78. , , , et al. T-cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol 2004; 113:155–60.
79. , , , et al. T-cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T-cells: results from a pilot study. Clin Exp Immunol 2003; 131:155–68.
80. , , , Myelin reactive T-cells after T-cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol 2000; 102:79–84.
81. , , , , MHC-restricted depletion of human myelin basic protein-reactive T-cells by T-cell vaccination. Science 1993; 261:1451–4.
82. , , , In vivo clonotypic regulation of human myelin basic protein-reactive T-cells by T-cell vaccination. J Immunol 1995; 155:5868–77.
83. , , , , Cellular and humoral immune responses against autoreactive T-cells in multiple sclerosis patients after T-cell vaccination. J Autoimmun 1999; 13:233–46.
84. , T-cell receptor V genes in multiple sclerosis: increased use of TCRAV8 and TCRBV5 in MBP-specific clones. Int Rev Immunol 1999; 18:9–36.
85. , , , et al. Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 1991; 88:9161–5.
86. , , , et al. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993; 362:68–70.
87. , , , , T-cell receptor V beta 5 and V beta 17 clonal diversity in cerebrospinal fluid and peripheral blood lymphocytes of multiple sclerosis patients. Mult Scler 1998; 4:154–61.
88. , , , et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996; 2:1109–15.
89. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25 +Treg cells. Curr Drug Targets Inflamm Allergy 2005; 4:217–29.
90. , , , et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 1994; 152:2510–19.
91. , , , et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008; 123:66–78.
92. , , , et al. Antibody-mediated suppression of Vbeta5.2/5.3(+) T-cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann Neurol 2002; 51:467–74.
93. , , , et al. Depletion of Vbeta5.2/5.3 T-cells with a humanized antibody in patients with multiple sclerosis. Eur J Neurol 2002; 9:153–64.
94. , , , , , Lymphocytapheresis in chronic progressive multiple sclerosis: results of a preliminary trial. Ann Neurol 1983; 14:593–4.
95. , , , Lymphocytapheresis in chronic progressive multiple sclerosis: immunologic and clinical effects. Neurology 1984; 34:922–6.
96. , , , Lymphocytapheresis therapy in multiple sclerosis, a preliminary study. Acta Neurol Scand 1984; 70:111–15.
97. , , , et al. Lymphocytoplasmapheresis in multiple sclerosis: one-year results in 6 patients. Ital J Neurol Sci 1986; 7:119–23.
98. , , Long-term lymphocytapheresis therapy in multiple sclerosis. Preliminary observations. Eur Neurol 1986; 25:225–32.
99. , , , et al. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet 1986; 1:1405–9.
100. , , , et al. Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol 1987; 22:634–8.
101. , , , et al. T-cell subsets and disease progression after total lymphoid irradiation in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1988; 51:980–3.
102. , , , et al. The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status. J Neurol Sci 1997; 152:182–92.
103. , , , et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49:351–7.
104. , , , et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692–8.
105. , , , et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T-cells. Nat Med 2006; 12:627–35.
106. , , , et al. In vitro induction of regulatory T-cells by anti-CD3 antibody in humans. J Autoimmun 2008; 30:21–8.
107. , , , et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995; 155:4521–4.
108. , , CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006; 24:233–8.
109. , , , et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67:1096–103.
110. , , , et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114–23.
111. , , , et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144:865–76.
112. , , , et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372:383–91.
113. , , , et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192:681–94.
114. , , , , IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T-cells via CD40-CD40 ligand interactions. J Neuroimmunol 2002; 125:134–40.
115. , , , et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996; 93:2499–504.
116. , , , , Monocyte-derived IL12, CD86 (B7–2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin Immunol 2003; 106:127–38.
117. , , Increased T-cell expression of CD154 (CD40-ligand) in multiple sclerosis. Eur J Neurol 2001; 8:321–8.
118. , , , , , Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment. Scand J Immunol 2000; 51:312–20.
119. , , , et al. Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182:1985–96.
120. , , , et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis [see comments]. Ann Neurol 1999; 45:695–703.
121. , , , et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996; 70:87–90.
122. , , , et al. Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 1998; 160:1514–21.
123. , , , , IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000; 165:548–57.
124. , , Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002; 51:165–74.
125. , , , , Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. J Neuroimmunol 2001; 117:156–65.
126. , , , et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol; 67:1055–61.
127. , The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424–35.
128. , , , Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87:949–54.
129. , , , Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170:607–12.
130. , , TNFalpha potentiates IFNgamma-induced cell death in oligodendrocyte progenitors. J Neurosci Res 1998; 54:574–83.
131. , , , , , Decreased IL-3 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J Neurol Sci 1993; 118:79–82.
132. , , , , , Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. Arch Neurol 1998; 55:793–8.
133. , , , et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2 +T-cells. Ann Neurol 1995; 38:723–30.
134. , , , , , Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78:318–23.
135. , , , et al. Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol 1996; 66:57–64.
136. . The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53:457–65.
137. , , , et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531–4.
138. , , , , Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. Neurology 2000; 55:192–8.
139. , , , , , Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 1999; 45:247–50.
140. , , Interferon beta decreases T-cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46:145–53.
141. , , , Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893–5.
142. , , , Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37:1097–102.
143. , , , et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 1998; 51:289–92.
144. , , , et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74:991–1003.